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Purpose: Nanoparticles are a promising alternative for ocular drug delivery, and our group has proposed that they are
especially suited for ocular mucosal disorders. The goal of the present study was to determine which internalization
pathway is used by cornea-derived and conjunctiva-derived cell lines to take up hyaluronic acid (HA)-chitosan oligomer
(CSO)-based nanoparticles (HA-CSO NPs). We also determined if plasmids loaded onto the NPs reached the cell nucleus.
Methods: HA-CSO NPs were made of fluoresceinamine labeled HA and CSO by ionotropic gelation and were conjugated
with a model plasmid DNA for secreted alkaline phosphatase. Human epithelial cell lines derived from the conjunctiva
and the cornea were exposed to HA-CSO NPs for 1 h and the uptake was investigated in living cells by fluorescence
microscopy. The influence of temperature and metabolic inhibition, the effect of blocking hyaluronan receptors, and the
inhibition of main endocytic pathways were studied by fluorometry. Additionally, the metabolic pathways implicated in
the degradation of HA-CSO NPs were evaluated by lysosome identification.
Results: There was intracellular localization of plasmid-loaded HACSO NPs in both corneal and conjunctival cells. The
intracellular presence of NPs diminished with time. HA-CSO NP uptake was significantly reduced by inhibition of active
transport at 4 °C and by sodium azide. Uptake was also inhibited by blocking hyaluronan receptors with anti-CD44
Hermes-1 antibody, by excess HA, and by filipin, an inhibitor of caveolin-dependent endocytosis. HA-CSO NPs had no
effect on cell viability. The transfection efficiency of the model plasmid was significantly higher in NP treated cells than
in controls.
Conclusions: HA-CSO NPs were internalized by two different ocular surface cell lines by an active transport mechanism.
The uptake was mediated by hyaluronan receptors through a caveolin-dependent endocytic pathway, yielding remarkable
transfection efficiency. Most of HA-CSO NPs were metabolized within 48 h. This uptake did not compromise cell viability.
These findings further support the potential use of HA-CSO NPs to deliver genetic material to the ocular surface.
Gene therapy can be broadly defined as the introduction
of genetic material into a cell for either the suppression of gene
expression or the production of a needed protein. Because the
eye  has  well  defined  anatomy,  immune  privilege,  and
accessibility, it is a promising candidate organ to benefit from
gene therapy. The ocular surface is covered by two protective
mucosal epithelia, the cornea and conjunctiva. These epithelia
are in direct contact with the tear film and act as barriers for
topically  administered  drugs.  Along  with  physiologic
mechanisms such as blinking and tear clearance, the epithelia
limit the efficient penetration of drugs and DNA into the eye.
To achieve efficient delivery of DNA to mucosal cell
nuclei,  several  barriers  must  be  overcome.  Among  the
different strategies explored to improve mucosal delivery, one
of  the  most  promising  is  the  use  of  mucoadhesive
nanoparticles (NPs) that are capable of interacting with the
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ocular mucosa. This interaction increases drug residence time
and promotes its transport across the ocular barriers [1]. Our
group  has  developed  NPs  consisting  of  bioadhesive  and
biocompatible polysaccharides, such as chitosan (CS) and
hyaluronic acid (HA), intended for gene delivery to the ocular
surface [2,3]. CS is a non-toxic and biocompatible cationic
polysaccharide  with  several  applications  for  the
administration of drugs and genes [4]. CS NPs interact and
remain  associated  with  the  ocular  mucosa  for  extended
periods of time [5], increasing the delivery to external ocular
tissues,  and  providing  long-term  drug  retention  [6].  In
contrast,  HA  is  an  acidic  mucopolysaccharide  distributed
widely in the eye. It has been used for the preparation of
microparticles [7] and as a coating material for preformed
liposomes [8], NPs [9], and plasmid DNA (pDNA) complexes
[10]. In previous studies by our group [2], we have shown that
NPs of HA and oligomers of CS (HA-CSO NPs) have the
ability  to  associate  with  significant  amounts  of  plasmid
pDNA,  enter  cells,  and  efficiently  deliver  the  pDNA.  In
rabbits, these NPs entered conjunctival and corneal epithelial
cells  without  causing  ocular  discomfort  or  irritation  and
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279without  significant  effects  on  tissue  morphology  and
functionality or tear production or drainage [11].
Improving  gene  delivery  requires  developing  an
understanding  of  the  cellular  uptake  mechanisms,
intracellular stability, and bioavailability of the therapeutic
DNA. Five major cell uptake mechanism are distinguished
[12]:  a)  macropinocytosis;  b)  phagocytosis;  c)  clathrin-
dependent  endocytosis;  d)  caveolin-mediated  endocytosis;
and  e)  clathrin-  and  caveolin-independent  pathways.
Macropinocytosis  and  phagocytosis  are  actin-dependent
endocytic mechanisms mainly used by cells to internalize
large amounts of fluids and growth factors (macropinocytosis)
or solid particles (phagocytosis). Endocytosis mediated by
clathrin and caveolins comprises multiple mechanisms that
allow cells to internalize macromolecules and particles into
transport vesicles derived from the plasma membrane [13].
Clathrin-dependent  endocytosis  enables  cargo  bound  to
specific membrane-bound receptors to be internalized [14].
Caveolins are the main protein component of caveolae, flask-
shaped invaginations of the plasma membrane that participate
in macromolecule internalization [15]. Finally, clathrin- and
caveolin-independent  pathways  transport  cargo  to  the
glycosylphosphatidylinositol-anchored-protein-enriched
early endosomal compartment [16].
The presence of HA in the HA-CSO NPs may facilitate
NP cellular uptake by receptor-mediated endocytosis. HA is
biocompatible, biodegradable, and mucoadhesive, and affects
several cellular processes. For instance, HA promotes corneal
wound  healing  through  regulation  of  epithelial  cell
regeneration and migration. This regulation is achieved by
binding of HA to two receptors, CD44 and the receptor for
hyaluronan-mediated motility (RHAMM) located in ocular
surface  epithelia  [17].  These  receptor-mediated  processes
may be implicated in the cellular uptake of HA-CSO NPs.
In  addition  to  internalization  mechanisms,  the
intracellular  trafficking  of  DNA-loaded  NPs  and
bioavailability of the transported DNA within the cell are
critical elements to study when a new drug carrier is proposed.
Among  these  issues,  the  degradation  of  the  NPs  in  the
lysosomes following their internalization is a key point [18].
Lysosomes  are  the  terminal  degradative  compartment  of
certain endocytic pathways [19] and may negate effective
drug targeting, in this case of pDNA, to the nucleus.
We propose that HA-CSO NPs may serve as an effective
gene delivery system for ocular surface disorders. Therefore,
the goal of the present work was to study the intracellular
trafficking of HA-CSO NPs loaded with a model pDNA. We
aimed  to  determine  which  HA-CSO  NP  internalization
pathways  are  used  by  corneal  and  conjunctival  cells  and
whether or not pDNA reaches the cell nucleus.
METHODS
Materials:  Plastic  culture  ware  was  obtained  from  Nunc
(Roskilde, Denmark). DMEM/F12 culture medium and other
cell culture reagents were from Invitrogen-Gibco (Inchinnan,
UK). Reagents 2,3-bis[2-methoxy-4-nitro-5sulfophenyl]-2H-
tetrazolium-5-carboxyanilide inner salt (XTT), sodium azide,
colchicine, chlorpromazine, and filipin were purchased from
Sigma-Aldrich  Corp.  (St.  Louis,  MO).  For
immunfluorescence  studies,  we  used  anticaveolin-1  (BD
Bioscience,  San  Jose,  CA)  and  anti-clathrin  (Affinity
Bioreagents, Rockford, IL) primary monoclonal antibodies
(Abs) and goat anti-mouse IgG F(ab´)2 PE-Cy5 (Santa Cruz
Biotechnology, Santa Cruz, CA) as a secondary antibody. The
Vibrant™Phagocytosis assay kit and LysoSensor® reagent
were  obtained  from  Molecular  Probes  (Leiden,  The
Netherlands).  The  fluorimetric  Sensolyte®  FDP  Secreted
Alkaline Phosphatase Reporter Gene Assay was purchased
from Anaspec (Fremont, CA) and the kit Label IT IT® Cy™3
from Mirus Bio LLC (Madison, WI).
Preparation of HA-CSO NPs: HA-CSO NPs were made of the
polysaccharides  HA  and  CSOs  by  a  slightly  modified
ionotropic  gelation  technique  [2].  Briefly,  375  µl  of  HA
solution (0.73 mg/ml), mixed with 50 µl of the crosslinker
tripolyphosphate (TPP, 0.59 mg/ml), was added over 750 µl
of CSO solution (0.625 mg/ml) with magnetic stirring. HA
was previously labeled with fluoresceinamine (fl-HA). CSOs
were obtained by sodium nitrite degradation as previously
described  by  Janes  et  al.  [20].  Briefly,  200  μl  of  0.1  M
NaNO2 were added to 4 ml of a 10 mg/ml chitosan solution.
The reaction was left overnight to complete the degradation,
and oligomers of approximately 10–12 kDa were recovered
by freeze-drying. HA-CSO NPs were loaded with a model
pDNA encoding secreted alkaline phosphatase (SEAP) by
incorporating  the  pDNA  in  the  HA/TPP.  The  theoretical
loading was set at 1% (W/W). The SEAP plasmid was labeled
with cyanine-3 (Cy-3), using the kit Label IT IT® Cy™3.
Physicochemical characterization and pDNA loading of HA-
CSO  NPs:  Mean  particle  size  and  size  distribution
(polidispersity)  were  measured  by  photon  correlation
spectroscopy. Also, Z-potential values were obtained by laser
Doppler anemometry. Stability of NPs upon storage at 4 °C
for up to two weeks was evaluated by periodically measuring
the size and Z-potential.
Cell lines and culture conditions: Three different cell lines
were  used.  The  IOBA-NHC  cell  line  is  a  nontransfected,
spontaneously immortalized conjunctival epithelial cell line
[21] used at passages 71 to 87. Cells were grown in DMEM/
F-12 supplemented with 10% fetal bovine serum (FBS), 5,000
U/ml penicillin, 5 mg/ml streptomycin, 2.5 μg/ml fungizone,
2  ng/ml  human  epidermal  growth  factor  (EGF),  1  µg/ml
bovine  insulin,  0.1  µg/ml  cholera  toxin,  and  0.5  µg/ml
hydrocortisone.
The HCE cell line is a SV40-immortalized human corneal
epithelial cell line [22]. Cells from passages 42 to 52 were
cultured in DMEM/F-12 supplemented with 15% FBS, 100
U/ml penicillin, 0.1 mg/ml streptomycin, 10 ng/ml EGF, 0.5%
DMSO, 5 μg/ml insulin, and 0.1 µg/ml cholera toxin.
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280The mouse macrophage RAW264.7 cell line [23] was
cultured in RPMI 1640 supplemented with 10% FBS, 5% L-
glutamine, 5% penicillin, and 5% streptomycin. It was used
as a control in the phagocytosis assay.
All cell lines were cultured at 37 °C in a 5% CO2%–95%
air atmosphere. Media were changed every other day, and
daily observations were made by phase contrast microscopy.
Cell  viability  assay:  Viability  of  20  µg/ml  HA-CSO  NP-
exposed cells was measured using the XTT toxicity test [24].
Cells were seeded onto 96-well plates (2×105 cells/well) and
grown until 75% confluence. Culture medium was replaced
with fresh phenol red-free RPMI, 48 h after NP incubation.
Then XTT solution was added and cells incubated at 37 °C
for  15  h.  Plates  were  read  in  a  SpectraMAX®M5
multidetection  microplate  reader  (Molecular  Devices,
Sunnyvale, CA) at 450 nm (reference wavelength: 620 nm).
Controls  included  cells  alone  and  cells  exposed  to  0.5%
benzalkonium chloride (BKC), which induces a significant
decrease of ocular cell viability in concentrations greater that
0.05% [25]. Cell viability was calculated as a percentage with
regard to control cells. Each test was repeated four times in
triplicate.
Uptake and trafficking experiments: Corneal and conjunctival
cell  lines  were  seeded  in  eight-well  multichamber
Permanox™ slides (5×105 cells/well) and 24-multiwell plates
(8×105 cells/well). When the confluent state was reached, cells
were washed out in supplement-free culture medium for 1 h,
and 100 µl of 20 µg/ml HA-CSO NPs were then added. After
1  h  incubation,  the  cells  were  washed  three  times  with
phosphate buffered saline (PBS) with 0.27% glucose, and
fresh medium was added. HA-CSO NP uptake was monitored
after 1, 6, 24, and 48 h by fluorescence microscopy and by
fluorometry.  Each  assay  was  performed  four  times  in
triplicate.
For fluorescence microscopy, living cells were viewed
under  an  inverted  fluorescence  microscope  (Leica  DMI
6000B, Wetzlar, Germany). Cell nuclei were counterstained
by Hoescht dye. To assure the intracellular location of the
NPs, vertical spatial images were generated by Z-scans in
1 µm steps for 20 images. For fluorometry, the cells were
washed to remove any extracellular NPs, then frozen, thawed,
and disrupted with 100 µl ice-cold radioimmunoprecipitation
assay (RIPA) buffer (10 mM Tris-HCl [pH 7.4], 150 mM
NaCl, 1% deoxycholic acid, 1% Triton X-100, 0.1% SDS, and
1 mM EDTA). Fluorescence in cell lysates was measured in
a SpectraMAX®M5 multidetection microplate reader at an
excitation wavelength of 490 nm and an emission wavelength
of 520 nm. The amount of NPs taken up by the cells was
expressed  in  arbitrary  units  of  fluorescence  intensity.
Negative  controls  included  cell  incubation  with  Hank's
balanced salt solution instead of NPs.
To explore different mechanisms of NP interaction with
epithelial cells and trafficking across the plasma membrane,
uptake of HA-CSO NPs was studied under seven different
blocking  conditions  (Table  1).  In  all  cases,  cells  were
incubated with the different inhibitors for 30 min before the
addition of the NPs, and then co-incubated with the NPs for 1
h.
The  phagocytic  capacity  of  both  the  corneal  and
conjunctival cell lines was studied to exclude phagocytosis as
a HA-CSO NP uptake pathway. The phagocytosis assay was
performed  using  the  Vibrant™Phagocytosis  assay  kit
following the manufacturer’s protocol. RAW264.7 cells were
used as control. Briefly, HCE, IOBA-NHC, and RAW264.7
cells  were  grown  in  96-well  plates  until  confluence.
Fluorescent Escherichia coli bioparticles were opsonized by
incubation with human serum for 1 h at 37 °C. The fluorescent
bioparticle  suspension  was  added  to  the  cultures  and
incubated at 37 °C. Negative controls included incubation
without bioparticles. After 2 h, the bioparticle suspension was
removed and a Trypan blue solution (0.25 mg/ml) was used
to quench the extracellular fluorescence. The fluorescence
associated with the phagocytosed bioparticles inside the cells
was  measured  in  a  SpectraMAX®M5  multidetection
microplate reader at an excitation wavelength 480 nm and an
emission wavelength of 529 nm. Results were expressed as
relative fluorescence units (RFU). Each assay was performed
five times in triplicate.
Immunofluorescence assays: HCE and IOBA-NHC cells were
seeded  onto  eight-well  multichamber  Permanox™  slides
(5×105 cells/well), grown until confluence, and incubated with
100 µl of 20 µg/ml HA-CSO NPs. After 1 h, the cells were
TABLE 1. UPTAKE PATHWAYS AND BLOCKING CONDITIONS.
Pathway Inhibitor Mechanism References
Phagocytosis - Vibrant™Phagocytosis assay kit (fluorescent E. coli bioparticles) [43]
Energy dependent processes 4 °C Blocks energy dependent processes [44]
  Sodium azide (100 mM) Inhibits ATP production. [45]
  Colchicine (15 mM) Inhibits endocytic processes [46]
HA-receptor-mediated pathway Hermes-1 (1 µg/100 µl) Blocks HA receptor CD-44 [47]
  Excess of HA (50×)* Blocks HA receptors [47]
Endocytosis Filipin (1.25 µg/ml) Specifically inhibits caveolin-mediated endocitosis [48]
  Chlorpromazine (25 µM) Specifically inhibits clathrin-mediated endocytosis [49]
           *50 fold with respect to the amount of HA forming the NPs.
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281washed three times with 0.27% glucose in PBS and fixed in
ice-cold methanol. After several washes with PBS, they were
incubated at room temperature (RT) for 50 min with blocking
buffer composed of PBS with 4% goat serum, 0.3% Triton
X-100, and 1% BSA to block the non-specific binding. Then
they were incubated with anti-caveolin-1 (0.25 µg/ml) or anti-
clathrin antibody (10 µg/ml) at 37 °C for 1 h. After several
washes  with  PBS,  cells  were  incubated  with  PE-Cy5-
conjugated secondary antibodies (4 µg/ml) for 1 h at RT. Cell
nuclei were counterstained by Hoescht dye. The preparations
were  viewed  under  an  epifluorescence  microscope.  Each
experiment was performed three times, and negative controls
included the omission of primary antibodies.
Degradative  pathways:  Lysosomes  in  living  cells  were
labeled and tracked by the fluorescent acidotrophic probe
LysoSensor®. HCE and IOBA-NHC cells were grown on
eight-well  multichamber  Permanox™  slides  (5×105  cells/
well) until confluence and then incubated with HA-CSO NPs
for  1  h.  After  incubation,  the  medium  was  removed  and
Lysosensor® (150 nM in DMEM culture medium) was added.
Cells were incubated for 3 min in 5% CO2 at 37 °C. Before
observation by microscopy, the solution was replaced with
fresh DMEM medium.
Transfection  assays:  The  yield  of  gene  expression  was
evaluated  by  monitoring  concentrations  of  SEAP  in  cells
exposed  to  pSEAP-loaded  HA-CSO  NPs,  using  the
fluorimetric Sensolyte® 3,6-fluorescein diphosphate (FDP)
SEAP reporter gene assay. Samples of culture medium were
prepared according to the manufacturer protocols 48 h after
NP incubation. The fluorogenic phosphatase substrate FDP
was used to assess the activity of generic phosphatase activity.
Fluorescein, the final hydrolytic product, was quantified by
excitation  at  485  nm  and  emission  at  528  in  a
SpectraMAx®M5  multidetection  microplate  reader.  Each
assay was performed four times in triplicate.
Statistical analysis: Statistical analyses were performed by a
biostatistician  (co-author  I.F.).  Results  were  expressed  as
means±standard  error  of  the  means.  The  statistical
significance  between  control  NP  treatment  and  inhibitor
effects at each time point was analyzed by ANOVA with three
fixed effects, using the Box-Cox transformation with λ=-1 to
verify the assumptions of normality, variance homogeneity,
and independence. Data from phagocytosis, transfection, and
viability assays were analyzed by ANOVA with two fixed
effects. After performing a Levene's test to assess the equality
of variances and a variance decomposition to determine how
much of the forecast error variance could be explained by the
model, pairwise comparisons were performed. Differences
were considered to be significant when p≤0.05.
RESULTS
Nanoparticle  characterization:  The  complete  physico-
chemical and morphological characterization of this kind of
NP has been reported [26]. The mean size of the HA-CSO NPs
was 104.6±0.2 nm, with a positive Z-potential of 31±0.6 mV,
and a polydispersity index of 0.167±0.022. Neither particle
size nor the Z-potential changed when the NPs were stored at
4 °C for up to 2 weeks (data not shown). Thus the NPs had
good stability during storage.
Uptake of plasmid-loaded HA-CSO NPs: Uptake of HA-CSO
NPs in the cultured corneal and conjunctival cell lines was
studied  by  fluorescence  microscopy.  After  HA-CSO  NP
incubation, the NPs appeared as nano-sized fluorescent dots
inside  the  cells  (Figure  1).  The  green  fluorescence  was
Figure 1. Fluorescence micrographs of
HA-CSO  NP  uptake  (6  h).
Fluoresceinamine-HA (green) and Cy3-
plasmid  (red)  were  evident  in  the
cytoplasm  of  HCE  and  IOBA-NHC
cells. Nuclei were counterstained with
Hoescht dye (blue). Insets show higher
magnification  of  cytoplasmic  NPs.
Representative images of four different
experiments are shown. (Magnification
63×, inset magnification 252×).
Molecular Vision 2011; 17:279-290 <http://www.molvis.org/molvis/v17/a34> © 2011 Molecular Vision
282Figure 2. Persistence of HA-CSO NPs over time. A: For both corneal and conjunctival cells, fluorescence intensity was greatest at 1 h after
incubation. By 6 h, the intensity diminished to approximately half, where it remained stable for up to 48 h. B: NP-associated fluorescence
diminished with time, as fluorescence micrographs at 1, 6, 24, and 48 h after treatment show. Uptake was higher in the HCE than in the IOBA-
NHC cells (n=4).
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283attributed to the fl-HA and the red fluorescence was attributed
to the Cy3-plasmid. Control cells exposed to Hank’s balanced
salt solution showed neither green nor red fluorescence, as
expected. In general, cells incubated with HA-CSO NPs had
a well preserved morphology that was similar to controls.
There was a sustained intracellular localization of plasmid-
loaded HA-CSO NPs in both corneal and conjunctival cell
lines (Figure 1). Uptake was always higher in corneal cells
compared  to  the  conjunctival  cells.  Plasmid  associated
fluorescence  (red)  was  localized  in  the  nucleus  or  in  the
perinuclear region after 24 and 48 h in both cell lines. At these
times,  most  of  the  red  fluorescence  was  independently
identified from the green fluorescence. Therefore, it can be
assumed the plasmid separated from the NPs and reached the
nucleus. Red-dotted fluorescence was more easily identified
in  HCE  than  in  IOBA-NHC  cells.  Different  Z-stacks
confirmed the intracellular localization of plasmid and NPs.
The  fluoresceinamine  fluorescence  signal  became
reduced  and  more  dispersed  as  the  time  of  incubation
increased (Figure 2), suggesting a process of intracellular
degradation. Cellular retention of NP-associated fluorescence
was quantified by fluorometry at 1, 6, 24, and 48 h. After 1 h,
uptake was confirmed in both cell lines, showing corneal cells
with higher cytoplasmic fluorescence levels than conjunctival
cells (Figure 2), although the differences were not significant.
The intracellular presence of NPs diminished with time, with
significantly higher levels at 1 h compared to 6, 24, and 48 h
(Figure 2).
Cell toxicity assays: Cell viability was measured in both cell
lines 48 h after removing the HA-CSO NPs. As expected,
BKC-exposed cells showed a very low viability percentage
(Figure 3). However, there were no significant differences in
cell viability between control corneal and conjunctival cell
lines and those exposed to 20 µg/ml of pSEAP-loaded HA-
CSO NPs.
Trafficking of HA-CSO NPs: To rule out phagocytosis as a
potential mechanism for HA-CSO NP uptake, the phagocytic
capacity of corneal and conjunctival cell lines was determined
by  fluorescent  opsonised  E.  coli  bioparticles.  The
fluorescence  associated  with  phagocytosed  bioparticles  in
corneal  and  conjunctiva  cell  lines,  11.36±0.58  RFU  and
10.45±0.46 RFU respectively, was significantly lower than in
the mouse macrophage RAW264.7 cell line, 85.831±10.82
RFU. Control uptake without bioparticles was 12.41±0.78
RFU.  Fluorescence  microscopy  showed  abundant  E.  coli
bioparticles  inside  the  RAW264.7  cells,  whereas  their
intracellular presence in corneal and conjunctival cell lines
were almost nil (data not shown). Therefore, HCE and IOBA-
NHC cells have negligible phagocytic capacity.
Endocytosis can be strongly inhibited with depletion of
cellular energy resources by lowered temperatures and with
metabolic inhibitors. The corneal and conjunctival cell lines
were incubated with HA-CSO NPs at 4 °C or with sodium
azide or colchicine at 37 °C. Uptake was significantly reduced
by incubation at 4 °C and by sodium azide (Figure 4A), both
of which inhibit active transport processes. Inhibition of NP
uptake by low temperature was significantly greater than that
by azide (p<0.05, Figure 4A). Colchicine did not reduce HA-
CSO NP uptake.
To  determine  if  the  main  HA  receptors,  CD44  and
RHAMM, were responsible for the cellular uptake of HA-
CSO NPs, we blocked them with an excess of HA and with
the anti-CD44 monoclonal antibody Hermes-1. HA-CSO NP
uptake was significantly reduced by Hermes-1 and excess HA
(Figure  4B).  While  the  reduction  in  uptake  by  Hermes-1
appeared to be more effective that excess HA, there were no
significant differences between them.
Figure 3. Cell viability 48 h after HA-
CSO  NPs  treatment.  Results  are
expressed  as  %  of  control  (C).
Benzalkonium cloride (BKC) was use
as  toxicity  control.  There  were  no
significant  differences  between  NP-
treated  and  non-treated  corneal  and
conjunctival cells (n=4).
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284To determine the kind of endocytic pathway implicated
in  the  HA-CSO  NP  uptake,  cells  were  incubated  with
chlorpromazine  (CPZ)  to  inhibit  clathrin-dependent
endocytosis  and  filipin  to  inhibit  caveolin-dependent
endocytosis. CPZ did not significantly affect HA-CSO NP
uptake by either corneal or conjunctival cells (Figure 4C).
However, the uptake of HA-CSO NPs in both cell lines was
significantly inhibited by filipin. Thus HA-CSO NP uptake is
mediated mainly by caveolin-dependent endocytosis.
Caveolin-1 and clathrin co-localization with HA-CSO NPs:
To  further  confirm  the  involvement  of  caveolin-mediated
processes in the uptake of HA-CSO NPs, we determined if the
staining pattern of caveolin-1 was associated with the NP
fluorescence.  Co-localization  of  NPs  and  caveolin-1  was
present in both cell lines at the plasma membrane and in the
cytoplasm,  probably  due  to  internalized  caveolin  vesicles
(Figure  5).  In  contrast,  while  clathrin  was  present  in  the
corneal and conjunctival cell lines, there was no remarkable
co-localization  between  it  and  the  NPs.  These  results  are
consistent with the inhibition of uptake by filipin and the lack
of inhibition by CPZ (Figure 4C).
Degradative  pathways:  To  determine  if  the  loss  of
fluorescence 6 h after uptake (Figure 2) was due to lyosomal
degradation, cells were incubated with NPs and then treated
with LysoSensor, a marker of lysosomes. NPs were not co-
localized  with  LysoSensor  in  the  lysosomal  compartment
after 24 (Figure 6) or 48 h. The presence of green fluorescent
NPs in the cytoplasm suggested that they were not subject to
lysosomal degradation. Altogether, these data implicated an
active NP degradation by a lysosome-independent process at
24 and 48 h.
HA-CSO NP transfection efficiency: The capacity of the HA-
CSO  NPs  to  transfect  cells  was  evaluated  48  h  after  NP
incubation. In this experiment we measured the concentration
of SEAP in cells exposed to HA-CSO NPs. pSEAP in solution
alone showed negligible transfection levels (data not shown).
However, the transfection levels in cells incubated with HA-
CSO  NPs  containing  pSEAP  were  significantly  increased
compared with controls (Figure 7). Transfection efficiency of
the corneal cell line was significantly higher than that of
conjunctival cell line.
DISCUSSION
NPs  are  alternative  drug  delivery  systems  that  have  the
potential for effective delivery of genetic material to the eye.
There are several studies in which NPs have been used for
ocular gene delivery [27,28], but most of them have problems
associated with toxicity, an invasive administration route, or
low  ability  to  reach  the  target  cells.  However,  we  have
reported that HA-CSO NPs have a suitable composition, size,
and Z-potential to ensure interaction with the ocular epithelia
[2], and that they are well tolerated by the ocular surface
[11].
In this work we studied the different pathways that may
be responsible for HA-CSO NP uptake and degradation by
human epithelial cell lines derived from the ocular surface.
We  also  evaluated  the  transfection  capability  of  pSEAP-
loaded HA-CSO NPs. For the two cell lines, HCE and IOBA-
NHC, HACSO NPs were internalized mainly by an active
transport mechanism mediated by HA receptors through a
caveolin-dependent  endocytic  pathway.  Fluorescence
microscopy  and  intracellular  NP-associated  fluorescence
quantification showed a remarkable intracellular localization
of HA-CSO NPs in both cell lines. These results are consistent
with our previous work with CS NPs that showed a similar
intracellular distribution [5].
Importantly,  the  plasmid-associated  fluorescence  was
localized in the nucleus or in the perinuclear region after 24
and  48  h.  This  localization  is  crucial  to  achieve  good
transfection efficiency. On internalization, HA is included in
the  non-lysosomal  vesicle  compartment  and  is  rapidly
accumulated in the perinuclear region and in cell nuclei [29,
30]. Therefore, the HA component of HA-CSO NPs may use
the same type of mechanism to lead the plasmid to the nuclear
compartment.
Figure 4. Inhibition of HA-CSO NP uptake. NP uptake was measured by fluorometry. A: Both azide and 4 °C significantly decreased NP
uptake in HCE (black bars) and IOBA-NHC (white bars) cells. B: Blocking the HA-receptors with Hermes-1 or with an excess of HA resulted
in a significant reduction of NP uptake. C: Filipin, a specific caveolin-dependent endocytosis inhibitor, significantly reduced HA-CSO NPs
uptake in both cell lines while CPZ, a specific clathrin-dependent endocytosis inhibitor, did not (*p-value<0.05; n=4).
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of HA-CSO NPs to enter the cornea-derived HCE cells was
higher than for conjunctiva-derived IOBA-NHC cells. This
difference could be associated with the expression of mucins
on  the  surface  of  the  IOBA-NHC  cells.  This  mucoid
component might hamper the interaction with the cellular
membrane and therefore the internalization of the NPs in
IOBA-NHC  cells,  as  we  have  shown  in  previous  studies
[31]. The minimal difference in uptake for the two cell lines
may be due to the presence of HA in the NPs. This could
improve the interaction of the NPs with the cells and enhance
internalization.
The intracellular presence of HA-CSO NPs decreased as
the  time  of  incubation  increased.  This  suggests  an  active
process of intracellular degradation, perhaps mediated by non-
lysosomal enzymes known to catabolize HA and CS, such as
hyaluronidases  [32],  chitinases  [33],  and  lysozymes  [34].
These  enzymes  are  present  in  the  ocular  surface  tissues
Figure 5. Caveolin-1 and clathrin immunofluorescence in HCE and IOBA-NHC cells after HA-CSO NP incubation. Caveolin expression was
higher than clathrin expression. Merged images showed co-localization of HA-CSO NP with caveolin (staining at arrowheads). Representative
images of four different experiments are shown.
Figure 6. Lysosensor staining in HCE
and  IOBA-NHC  cells.  At  24  h  after
incubation, both HA-CSO NPs (green)
and  Lysosensor-stained  lysosomes
(blue) were present in both cell lines.
However there was no evidence of NP
colocalization  with  lysosomes.
Representative images of four different
experiments are shown.
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this study needs further clarification.
The viability of treated corneal and conjuctival cell lines
was totally preserved. This is in agreement with previous in
vitro [2] and in vivo [11] works for these nanosystems. It
indicates an adequate level of safety for the application of HA-
CSO NPs in the ocular surface. Other evidences of the safe
application of NPs to the ocular surface have been reported
[38].
For  any  drug,  understanding  the  initial  mode  of
internalization is the first step in achieving optimized drug
delivery. HA-CSO NPs uptake is energy-dependent as shown
by its inhibition with low temperature and sodium azide. This
is consistent with previous works that indicate that cargo
uptake is usually energy-dependent [13]. Internalization of
substances  typically  occurs  by  macropinocytosis,
phagocytosis,  clathrin-dependent  endocytosis,  caveolin-
mediated endocytosis, or clathrin- and caveolin-independent
pathways  [15].  We  did  not  study  the  macropinocytosis
pathway because it involves internalization of relatively large
particles (1–5 μm diameter), much larger than the HA-CSO
NPs,  which  averaged  104.6  nm.  Phagocytosis  is  usually
associated  with  specialized  cells  [12],  although  some
epithelial cells are also capable of it [39]. However, we found
that  the  capacity  for  phagocytosis  of  the  ocular  surface
epithelial cells in vitro was negligible.
Figure  7.  Evaluation  of  NP  transfection  efficiency.  Transfection
levels were significantly higher in pSEAP-loaded HA-CSO NP-
transfected  cells  (NPs)  than  in  control  cells  (C;  *p<0.05).  HCE
transfection efficiency was significantly higher than IOBA-NHC
efficiency (#p<0.05; n=4).
According to our previous results, the presence of HA in
the  NPs  would  ease  access  to  corneal  and  conjunctival
epithelial cells that express the hyaluronan receptor CD44.
Accordingly, we found that HA-CSO NP uptake was blocked
by the monoclonal antibody Hermes-1 for the CD44 receptor
as well as by an excess of HA, suggesting that these NPs enter
the cell by a receptor-mediated process. CD44 is the primary
cell surface receptor for HA in the ocular surface epithelia
[17], and it binds HA with five times greater affinity than
RHAMM [40]. Excess HA also decreased NP uptake, but the
inhibition was somewhat less than that by Hermes-1 antibody,
possibly due to more effective blocking by the monoclonal
antibodies. Recently, we found that CD44 expression is higher
in human corneal than in conjunctival tissues (unpublished).
This is consistent with the higher uptake of HA-CSO NP by
corneal than by conjunctival cell line. Therefore, there may
be a correlation between CD44 expression and HA-CSO NP
uptake. RHAMM also has the capability to bind HA, although
cell surface CD44 function is dominant [41]. Even though we
cannot rule out the participation of RHAMM in the HA-CSO
NP uptake, it seems to be much less important than CD44.
Endocytosis is a basic cellular process that is used by all
cell types to internalize a variety of molecules by means of
two different specialized proteins: clathrin and caveolin [15].
CPZ, a specific inhibitor of clathrin-dependent endocytosis,
did not significantly affect HA-CSO NP uptake. In contrast,
filipin, a specific inhibitor of caveolin-dependent endocytosis,
significantly reduced NP uptake. In addition, attempts to co-
localize  antibody-labeled  clathrin  with  the  NPs  were  not
successful, while antibody-labeled caveolin-1 did co-localize
with HA-CSO NPs. Caveolin-dependent endocytosis occurs
quickly, in less than 20 min [13]. Our results are in agreement
with that, as we observed an abundance of NPs inside the cells
after 1 h incubation. These findings suggest that HA-CSO NPs
are mainly internalized by the caveolin-mediated endocytosis
pathway.
The  degradation  pathway  of  NPs  following
internalization is another important aspect of intracellular NP
dynamics. Degradation by lysosomes is a common terminal
destination  for  the  endocytic  pathway  [19].  However,
lysosomes and HA-CSO NPs were not co-localized in the
cytoplasm  after  24  and  48  h,  suggesting  that  vesicles
containing the NPs probably were not directed there following
uptake. However, it is possible that there was a degree of
elimination by lysosomes before 6 h. The CD44 receptor and
HA  are  associated  with  caveolae,  and  the  caveolar
internalization pathway bypasses lysosomes [42]. Thus it is
not surprising that we found no evidence of NP degradation
by lysosomes.
Based on these data, we propose that the main HA-CSO
NP uptake pathway begins with the interaction of the HA
component  of  the  HA-CSO  NPs  and  CD44  followed  by
caveolae internalization. Caveosomes are large subcellular
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is  responsible  for  sorting  the  vesicle  contents  [42].
Internalized caveolae loaded with HA-CSO NPs may fuse
with  caveosomes  that  then  deliver  the  NPs  into  other
subcellular compartments, typically to the Golgi network or
to the ER and subsequently to the nucleus (Figure 8). More
studies are needed to clarify the complete pathway.
The final goal of a gene delivery system is to produce a
significant level of gene transfection. HA-CSO NPs loaded
Figure 8. Proposed HA-CSO NP internalization pathway. HA-CSO
NPs  interact  with  CD44  receptors  in  the  plasma  membrane,
triggering the internalization of the caveola vesicles that then fuse
with the caveosome. From the caveosome, NPs are sorted to the
endoplasmic reticulum (ER) and then to the nucleus. CD44 receptors
and caveolin are then recycled and carried back to the membrane
through the Golgi network.
with  SEAP  pDNA  yielded  significant  transfection  of  the
corneal and conjunctival cell lines. Transfection efficiency of
the HCE cells was significantly higher than that of the IOBA-
NHC cells. Taking into account that NP uptake was also
higher  in  HCE  cells,  we  believe  that  the  internalization
process is the limiting step for the efficiency of these delivery
systems as transfection vehicles. At least for the cell lines
studied, HA-CSO NPs are a suitable gene delivery system.
To  conclude,  we  propose  that  HA-CSO  NPs  are
internalized by corneal and conjunctival cell lines by an active
transport  mechanism  mediated  mainly  by  the  CD44  HA
receptor through a caveolin-dependent endocytic pathway.
Using this pathway, plasmid-loaded HA-CSO NPs achieved
significant  transfection  efficiency.  These  NPs  did  not
compromise cell viability and most of them were metabolized
by the ocular surface epithelial cell lines in 48 h. These facts
further support the potential use of HA-CSO NPs to deliver
genetic material to the ocular surface.
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